Inclusion Criteria:

          1. Properly completed patient informed consent

          2. Male or female aged at least 18 years

          3. Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR
             mutations including L858R and/or Exon19Del. EGFR mutation status will be determined by
             local or central laboratory testing on tumour tissue or plasma utilizing a validated
             methodology which has been approved by the regulatory authority.

          4. No prior treatment with chemotherapy, EGFR-TKIs, or biological therapies that are
             considered first line treatment for advanced NSCLC.

          5. All patients must have a documented diagnosis of advanced (Stage IV) NSCLC with
             Magnetic Resonance Imaging (MRI) documented CNS metastases that include brain
             metastases (BM). BM + patients with co- existent leptomeningeal involvement are
             eligible for the study.

          6. Eligible patients are not candidates for definitive surgical resection or radiation of
             all lesions in the opinion of the treating physician.

          7. All patients must be stable without any systemic (oral or parenteral) corticosteroid
             or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled
             non-absorbable and topical corticosteroid use are permitted as indicated.

          8. Patients may have prior placement of a properly functioning CNS shunt or Ommaya
             reservoir.

          9. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no
             deterioration over the previous 2 weeks.

         10. Women of child-bearing potential and male subjects shall agree to take medically
             acceptable contraception measures while on study treatment and for 3 months following
             completion of study treatment. All women of child-bearing potential must have a
             negative blood pregnancy test at screening.

         11. (a) For Patients with measurable CNS lesions must have AT LEAST ONE site of CNS
             lesion, which was not previously irradiated, that can be accurately measured at
             baseline as ≥ 10 mm in the longest diameter by MRI and which is suitable for accurate
             repeated measurements. Measurable extracranial disease is not required. (b) For
             Patients with non-measurable CNS lesions must have AT LEAST ONE extracranial lesion,
             which has not been previously irradiated, within the screening period that can be
             accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes
             which must have short axis ≥ 15 mm) by CT/MRI and are suitable for accurate repeated
             measurement.